The table below shows Allogene Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$12.91M
-$52.93M
-$55.90M
-$66.64M
-$68.24M
-$49.33M
Capital expenditure
$9.00K
$99.00K
$8.00K
$1.03M
$1.90M
$6.46M
Investing cash flow
-$29.59M
$6.18M
$22.13M
$112.94M
-$22.38M
$96.80M
Dividends paid
-
-
-
-
ALLO operating cash flow (10-K history)
Allogene Therapeutics, Inc. reported operating cash flow of -$149.25M for fiscal year 2025. That is up 25.5% from -$200.30M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$44.65M (FY 2018) to -$149.25M. Figures come from the company's audited annual reports as filed with the SEC.